Cardiovascular Disease | Pharma Marketer

Remember Apo-A1 Milano? Pfizer Does.

Monday, January 4th, 2010

The folks over at the In Vivo Blog will soon be announcing their “Deal of the Year” in the biotech/pharma sector (you can scroll back over there to see the various nominees). But they could just as well run the competition in reverse, and award some retroactive Bad Deal statues based on what’s been happening recently.

Posted in: In the Pipeline | 0 Comments »

Read the full story

Mipomersen – It Still Works

Wednesday, May 20th, 2009

Isis Pharmaceuticals has had a long, tough history developing antisense-based therapeutics. I’ve lost count of the number of promising candidates they’ve had (and promising deals they’ve signed). But the latest one seems to be progressing: mipomersen , designed to block production of the ApoB lipoprotein

Posted in: In the Pipeline | 0 Comments »

Read the full story

Farewell to ACAT, and to Lots of Time and Money, Too

Tuesday, May 5th, 2009

Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had already been a drug target for some years before I first heard about it, and has remained one.

Posted in: In the Pipeline | 0 Comments »

Read the full story

Change4life TV commercial

Friday, April 24th, 2009

Click on image to view the commercial 60 active minutes, just one of the ways to change for life (change4life). Search ‘change4life’ or call 0300 123 4567 Agency: M&C Saatchi 2009